



Clinical Edit Criteria Proposal

Drug/Drug Class: **Miralax Clinical Edit**
 Date: **March 18, 2004**
 Prepared for:
 Prepared by: **Missouri Medicaid**

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: Monitor the use of Miralax Powder for Oral Solution as first line treatment of constipation.

Why was this Issue Selected: Miralax prescription claims are significantly more expensive to the pharmacy program than other drugs prescribed for constipation. The average Miralax prescription costs the program \$35.42. The average prescription claim for non-prescription laxatives costs the program \$9.16.

Program-specific information:	Drug	Claims	Expense
	• Miralax Powder	35,126	\$1,244,181
	• Docusate 100mg Caps	16,534	\$144,948
	• Dulcolax 5mg Tabs	2,731	\$23,080
	• Senokot-S Tabs	3,212	\$37,975

Setting & Population: Patients 18 years of age and older

Type of Criteria:

Increased risk of ADE **Non-Preferred Agent**

Effectiveness **Other:**

Data Sources: **Only administrative databases** **Databases + Prescriber-supplied**

Setting & Population

- Drug/drug class for review: Miralax
- Age range: All patients 18 years of age and older
- Gender: males and females

Approval Criteria

- Appropriate diagnosis - Constipation
- Trial and failure on at least 2 different covered laxative preparations
- ADE/ADR to covered laxative products
- Contraindication to covered laxative products

Denial Criteria

- No prior prescription claims for covered laxative product in the most recent 45 days
- Lack of ADE/ADR and/or lack of contraindication to covered laxative products
- Lack of appropriate diagnoses

Required Documentation

Laboratory results:
MedWatch form:

Progress notes:

Disposition of Edit

- **Denial:** Edit 682 "Clinical Edit"

References

1. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2003.
2. Facts and Comparisons, pg. 1166-1177; 2004.

